The abstract is read at the publisher; the summary is JClub's.
In the OPTI-AML randomized phase 2 trial in older adults with untreated ND-AML, 14-day venetoclax induction with azacitidine did not meet noninferiority versus 28-day dosing for CR within 2 cycles (43% vs 49.4%).
- Why it matters: Prolonged cytopenias and frequent modifications with the approved 28-day venetoclax schedule create a need for prospective evidence on whether shorter induction can preserve efficacy while reducing toxicity.
- What they did: Between 2023 and 2025, 169 patients aged ≥60 years received azacitidine 75 mg/m2 for 7 days with either 28-day (n=83) or 14-day (n=86) venetoclax for cycles 1–2, with CR within 2 cycles as the primary endpoint.
- The result: CR was 49.4% with AV28 versus 43% with AV14 (difference 6.4%, 90% CI -6.1% to 19.0%), and although MRD negativity was similar (77.6% vs 76.5%), AV14 did not support routine abbreviation during initial therapy.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.